search
Back to results

A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery

Primary Purpose

Single Ventricle Cardiac Anomaly

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Tissue Engineered Vascular Grafts
Sponsored by
Christopher Breuer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Single Ventricle Cardiac Anomaly focused on measuring tissue engineered vascular graft

Eligibility Criteria

1 Year - 100 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • single ventricle cardiac anomaly requiring extra cardiac total cavopulmonary connection (EC TCPC).

Exclusion Criteria:

  • incomplete inferior vena cava (IVC)

Sites / Locations

  • Nationwide Children's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Tissue Engineered Vascular Grafts

Arm Description

Outcomes

Primary Outcome Measures

graft failure requiring intervention

Secondary Outcome Measures

graft growth

Full Information

First Posted
January 29, 2008
Last Updated
February 28, 2018
Sponsor
Christopher Breuer
Collaborators
Doris Duke Charitable Foundation, Gunze Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01034007
Brief Title
A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery
Official Title
A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
December 2009 (undefined)
Primary Completion Date
December 26, 2017 (Actual)
Study Completion Date
January 23, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Christopher Breuer
Collaborators
Doris Duke Charitable Foundation, Gunze Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An initial feasibility and safety study evaluating the use of autologous tissue engineered vascular grafts as extra cardiac total cavopulmonary connection (EC TCPC) conduits in children with single ventricle anomalies.
Detailed Description
This investigation is a prospective, nonrandomized phase 1 clinical trial determining the safety of the use of tissue engineered vascular grafts as conduits for EC TCPC. Primary end points of the study will include determination of graft failure rates and graft related morbidity and mortality. Graft failure will be defined as any graft narrowing/occlusion or dilation/rupture requiring surgical or endovascular intervention. Graft related morbidity and mortality will include any post-operative complication such as any thromboembolic or infectious event that requires treatment and is thought likely to be caused by the tissue engineered vascular graft as determined by the investigators and confirmed by the data safety monitoring board. All appropriate patients requiring EC TCPC who meet study inclusion/exclusion criteria will be evaluated for enrollment in the clinical trial. After obtaining informed consent from the patient's parents, patients with single ventricle cardiac anomalies will undergo EC TCPC using a tissue engineered conduit. Post-operative care and monitoring will follow an established, standardized, clinical algorithm in which the patient's clinical status including complications and measurements of graft function will be serially evaluated and recorded over a three year period using physical examination, echocardiography, and MRA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Single Ventricle Cardiac Anomaly
Keywords
tissue engineered vascular graft

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tissue Engineered Vascular Grafts
Arm Type
Experimental
Intervention Type
Combination Product
Intervention Name(s)
Tissue Engineered Vascular Grafts
Intervention Description
Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
Primary Outcome Measure Information:
Title
graft failure requiring intervention
Time Frame
3 years
Secondary Outcome Measure Information:
Title
graft growth
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: single ventricle cardiac anomaly requiring extra cardiac total cavopulmonary connection (EC TCPC). Exclusion Criteria: incomplete inferior vena cava (IVC)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher K Breuer, MD
Organizational Affiliation
Nationwide Children's Hospital, Columbus, Ohio
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Toshiharu Shinoka, MD/PhD
Organizational Affiliation
Nationwide Children's Hospital, Columbus, Ohio
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mark Galantowicz, MD
Organizational Affiliation
Nationwide Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery

We'll reach out to this number within 24 hrs